SEC Form 4 · accession 0001209191-18-020968
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter S Klein
Director
Period of report
Mar 16, 2018
Accepted (ET)
Mar 20, 2018 · 6:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $21.535 | Mar 16, 2018 | A | 37,954 | A | — | Mar 15, 2028 | Common Stock | 37,954 | 37,954 | D |
Explanation of responses
- F125% of the shares subject to the option will vest on March 16, 2019 and an additional 1/48 of the shares vest monthly thereafter.